Fabricio Furlan

Hexal AG (a Sandoz company), Germany

Poster(s):

• E0388 - A Randomized Phase I Study Comparing Pharmacokinetics, Safety and Immunogenicity of High Concentration Formulation (100 mg/mL) With GP2017 Formulation (50 mg/mL), an Adalimumab Biosimilar, in Healthy Male Subjects
  Tuesday, October 25, 2022

  3:00 PM – 5:00 PM ET